Top Page
HCW Biologics
(NASDAQ:HCWB)
HCW Biologics (HCWB) vs. SPDR S&P 500 ETF (SPY)
HCW Biologics Business Overview & Revenue Model
HCW Biologics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 832.84K | 2.57M | 2.84M | 6.72M | 0.00 | 4.10M |
| Gross Profit | -515.94K | 959.40K | 560.36K | 2.59M | -543.60K | 4.10M |
| EBITDA | -11.42M | -27.68M | -23.58M | -14.18M | -12.82M | -5.25M |
| Net Income | -21.55M | -30.02M | -24.99M | -14.72M | -12.36M | -5.78M |
Balance Sheet | ||||||
| Total Assets | 28.91M | 30.24M | 28.51M | 46.81M | 53.51M | 15.40M |
| Cash, Cash Equivalents and Short-Term Investments | 2.44M | 4.67M | 3.60M | 32.06M | 36.71M | 8.46M |
| Total Debt | 6.42M | 13.69M | 6.30M | 6.41M | 0.00 | 567.31K |
| Total Liabilities | 28.96M | 37.01M | 15.05M | 9.38M | 2.32M | 1.00M |
| Stockholders Equity | -51.97K | -6.77M | 13.46M | 37.43M | 51.19M | 14.40M |
Cash Flow | ||||||
| Free Cash Flow | -12.71M | -14.49M | -28.72M | -20.66M | -11.02M | -10.62M |
| Operating Cash Flow | -12.56M | -14.23M | -22.51M | -10.39M | -10.98M | -10.43M |
| Investing Cash Flow | -150.47K | -261.62K | 3.80M | 14.71M | -35.02M | -186.68K |
| Financing Cash Flow | 13.99M | 15.57M | -14.53K | 6.27M | 49.27M | 11.72M |
HCW Biologics Technical Analysis
HCW Biologics Risk Analysis
HCW Biologics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $8.67M | ― | -61.65% | ― | -80.31% | -293.92% | |
| ― | $8.79M | -0.78 | -43.39% | ― | -100.00% | 49.47% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $8.14M | -0.41 | -146.46% | ― | ― | 24.30% | |
| ― | $9.13M | -2.01 | -51.83% | ― | -2.94% | 34.52% | |
| ― | $8.43M | ― | ― | ― | -78.77% | 61.32% | |
| ― | $7.54M | -0.21 | ― | ― | ― | 91.46% |
HCW Biologics Corporate Events
On August 19, 2025, HCW Biologics Inc. received notice from Nasdaq that it was non-compliant with the Equity Rule for continued listing. Following a hearing on September 25, 2025, the Nasdaq Hearings Panel granted the company an extension to regain compliance, requiring it to meet all listing rules by February 16, 2026. The company must also notify Nasdaq of significant events affecting compliance and file necessary documentation for review.
The most recent analyst rating on (HCWB) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
HCW Biologics Inc. and WY Biotech Co., Ltd. have agreed to extend the payment date for a $7.0 million upfront license fee under their worldwide exclusive license agreement to September 30, 2025. However, WY Biotech has not finalized necessary agreements with its partners and may not meet the new deadline, prompting ongoing negotiations for further revisions to the agreement.
The most recent analyst rating on (HCWB) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
On June 26, 2025, HCW Biologics Inc. announced that it had received formal notice from Nasdaq confirming its compliance with the Equity Rule for continued listing on the Nasdaq Capital Market. However, the company remains under a Panel Monitor until June 23, 2026, and must request a hearing to address any future non-compliance. On August 19, 2025, HCW Biologics was notified of non-compliance as of June 30, 2025, risking suspension of its securities from trading on Nasdaq unless a hearing is requested by August 26, 2025. The company plans to request a hearing to stay the suspension and is exploring options to regain compliance, though there is no assurance of success.
The most recent analyst rating on (HCWB) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
HCW Biologics Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending on June 30, 2025. The primary reason for this delay is the additional time required to prepare the financial statements for the quarter. The company has assured stakeholders that the report will be filed within the five-day grace period allowed by the Securities Exchange Act of 1934. HCW Biologics anticipates significant changes in its financial results compared to the previous year, largely due to a substantial decrease in legal fees from $10.4 million in Q2 2024 to $142,452 in Q2 2025, following the settlement of a long-running arbitration. The notification was signed by Rebecca Byam, the Chief Financial Officer, who confirmed the company’s commitment to compliance and timely filing.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
On August 14, 2025, HCW Biologics Inc. and Square Gate Capital Master Fund, LLC- Series 4 amended their Equity Purchase Agreement to allow multiple purchases and sales of shares on the same trading day. This amendment could enhance the company’s financial flexibility by enabling more dynamic trading of its shares, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.